EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

JDB-1-200, an Atypically Modified Carbapenem with Standalone In Vitro Activity against KPC-Producing Enterobacterales

Taariq Hassan, Svanik Jaikumar, Diya Patel, Pojun Quan, Maidileyvis Castro Cabello, Jonathan E Cox iD, Md Mahbub Kabir Khan, James Spencer iD, Catherine L Tooke, John D Buynak iD

ACS Infectious Diseases · 09.10.2026 · 12 (10) · 3514-3529

DOI: 10.1021/acsinfecdis.6c00607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 08.09.2026. Verfasst von Taariq Hassan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Southern Methodist University, Dallas, Texas75275, United States. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, beta-Lactamases, Carbapenems, Bacterial Proteins. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, Medical Research Council Career Development Award, University of Bath Prize Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem-resistant Enterobacterales (CRE), including Escherichia coli and Klebsiella pneumoniae are increasingly common pathogens. Resistance in CRE is often associated with production of K. pneumoniae (KPC) carbapenemases. We report a structurally modified meropenem derivative, JDB-1-200 (i.e., 8-epi-meropenem, in which the stereochemistry of the C8 hydroxyl is inverted), displaying enhanced activity relative to meropenem against KPC-producing CRE. JDB-1-200 alone displayed superior activity (MICs of 0.5 to 1 mg/L, compared with >8 mg/L for meropenem) against several clinically relevant Enterobacterales, including KPC-producing K. pneumoniae and Citrobacter freundii. Crystallographic analysis of JDB-1-200 complexes with the E166Q deacylation-deficient KPC-2 mutant, compared with an analogous meropenem (8R-hydroxyl) complex, indicates that the improvement arises from the JDB 8S-hydroxyl group acting as a hydrogen-bond donor to the hydrolytic water, slowing acyl-enzyme hydrolysis, with similar interactions observed in a CTX-M-15:JDB-1-200 complex. Kinetic inhibition data for KPC-2 and CTX-M-15 indicate that JDB-1-200 could be used alone or alongside a β-lactamase inhibitor for effective CRE treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial Agentsbeta-LactamasesCarbapenemsBacterial ProteinsKlebsiella pneumoniaeCarbapenem-Resistant EnterobacteriaceaeMicrobial Sensitivity TestsMeropenemEscherichia coliCrystallography, X-RayCitrobacter freundiiModels, Molecular

Stichwörter der Autor:innen

Klebsiella pneumonia carbapenemaseCarbapenem Resistant EnterobacteralesCrystallographic analysisMechanism of actionStructurally modified carbapenem antibiotics

Substanzen

Anti-Bacterial Agentsbeta-LactamasesCarbapenemsBacterial ProteinsMeropenem

Autor:innen und Institutionen

  • Department of Chemistry, Southern Methodist University, Dallas, Texas75275, United States.
  • School of Cellular and Molecular Medicine, University of Bristol, Biomedical Sciences Building, University Walk, BristolBS8 1TD, U.K.
  • Department of Life Sciences and Centre of Evolution, University of Bath, Claverton Down, BathBA2 7AY, U.K.

ORCID-Profile: Jonathan E Cox, James Spencer, John D Buynak

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • Medical Research Council Career Development Award, University of Bath Prize Fellowship
  • Medical Research Council
  • National Institutes of Health

Zitieren

APA

Hassan, T., Jaikumar, S., Patel, D., Quan, P., Cabello, M. C., Cox, J. E., Khan, M. M. K., Spencer, J., Tooke, C. L., & Buynak, J. D. (2026). JDB-1-200, an Atypically Modified Carbapenem with Standalone In Vitro Activity against KPC-Producing Enterobacterales. ACS Infectious Diseases, 12(10), 3514-3529. https://doi.org/10.1021/acsinfecdis.6c00607

Vancouver

Hassan T, Jaikumar S, Patel D, Quan P, Cabello MC, Cox JE, et al. JDB-1-200, an Atypically Modified Carbapenem with Standalone In Vitro Activity against KPC-Producing Enterobacterales. ACS Infectious Diseases. 2026;12(10):3514-3529. doi:10.1021/acsinfecdis.6c00607

BibTeX
@article{Hassan2026,
  author = {Hassan, Taariq and Jaikumar, Svanik and Patel, Diya and Quan, Pojun and Cabello, Maidileyvis Castro and Cox, Jonathan E and Khan, Md Mahbub Kabir and Spencer, James and Tooke, Catherine L and Buynak, John D},
  title = {JDB-1-200, an Atypically Modified Carbapenem with Standalone In Vitro Activity against KPC-Producing Enterobacterales},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {10},
  pages = {3514--3529},
  doi = {10.1021/acsinfecdis.6c00607}
}
Kostenlos starten →